title: BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
abstract: Cancer germline (CG) genes are normally expressed in germ cells and aberrantly expressed in a variety of cancers; their immunogenicity has led to the widespread development of cancer vaccines targeting these antigens. BORIS/CTCFL is an autosomal CG antigen and promising cancer vaccine target. BORIS is the only known paralog of CTCF, a gene intimately involved in genomic imprinting, chromatin insulation, and nuclear regulation. We have previously shown that BORIS is expressed in epithelial ovarian cancer (EOC) and that its expression coincides with promoter and global DNA hypomethylation. Recently, 23 different BORIS mRNA variants have been described, and have been functionally grouped into six BORIS isoform families (sf1-sf6). In the present study, we have characterized the expression of BORIS isoform families in normal ovary (NO) and EOC, the latter of which were selected to include two groups with widely varying global DNA methylation status. We find selective expression of BORIS isoform families in NO, which becomes altered in EOC, primarily by the activation of BORIS sf1 in EOC. When comparing EOC samples based on methylation status, we find that BORIS sf1 and sf2 isoform families are selectively activated in globally hypomethylated tumors. In contrast, CTCF is downregulated in EOC, and the ratio of BORIS sf1, sf2, and sf6 isoform families as a function of CTCF is elevated in hypomethylated tumors. Finally, the expression of all BORIS isoform families was induced to varying extents by epigenetic modulatory drugs in EOC cell lines, particularly when DNMT and HDAC inhibitors were used in combination.
authors: Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors: Petra A
authors: PA
authors: Link
authors: Wa
authors: W
authors: Zhang
authors: Kunle
authors: K
authors: Odunsi
authors: Adam R
authors: AR
authors: Karpf
mesh_terms: D000077216:Carcinoma, Ovarian Epithelial; D019175:DNA Methylation; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D044127:Epigenesis, Genetic; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020084:Long Interspersed Nucleotide Elements / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics*; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013737:Testis / Q000378:metabolism
chemical_list: C456540:CTCFL protein, human; D004268:DNA-Binding Proteins; D020033:Protein Isoforms; D012333:RNA, Messenger
keywords: BORIS; CTCF; DNA methylation; epigenetics; ovarian cancer
references: Cancer Res. 2005 Sep 1;65(17):7763-74
references: 16140944
references: J Cell Physiol. 2012 Feb;227(2):479-92
references: 21465478
references: Nature. 2011 Jun 29;474(7353):609-15
references: 21720365
references: Nucleic Acids Res. 2007;35(21):7372-88
references: 17962299
references: BJOG. 2012 Jan;119(2):134-6
references: 22168761
references: Br J Cancer. 2008 Feb 12;98(3):571-9
references: 18195709
references: Cancer Immun. 2007 Dec 21;7:21
references: 18095639
references: Epigenetics. 2006 Jul-Sep;1(3):116-20
references: 17786175
references: Future Oncol. 2010 May;6(5):717-32
references: 20465387
references: Nat Rev Cancer. 2005 Aug;5(8):615-25
references: 16034368
references: Cell Immunol. 2011;270(2):188-97
references: 21641588
references: J Immunol. 2007 Jan 1;178(1):566-73
references: 17182597
references: Int J Cancer. 2008 Feb 15;122(4):777-84
references: 17957795
references: Clin Cancer Res. 2008 Jun 1;14(11):3283-90
references: 18519754
references: Clin Cancer Res. 2011 Apr 15;17(8):2170-80
references: 21296871
references: PLoS One. 2010 Nov 08;5(11):e13872
references: 21079786
references: Clin Cancer Res. 2009 Sep 1;15(17):5323-37
references: 19723653
references: Gene Ther. 2008 Jan;15(1):61-4
references: 17972923
references: Nucleic Acids Res. 2011 Feb;39(3):862-73
references: 20876690
references: Nat Genet. 1999 Jan;21(1):103-7
references: 9916800
references: Cancer Res. 2005 Sep 1;65(17):7751-62
references: 16140943
references: Cancer Immun. 2010 Jul 23;10:6
references: 20649179
references: Oncogene. 2002 Aug 12;21(35):5496-503
references: 12154410
references: J Transl Med. 2011 Dec 14;9:213
references: 22168535
references: Semin Cancer Biol. 2002 Oct;12(5):399-414
references: 12191639
references: PLoS Genet. 2008 Aug 29;4(8):e1000169
references: 18769711
references: Nat Med. 2011 Aug 04;17(8):916-8
references: 21818078
references: PLoS One. 2012;7(6):e39371
references: 22724006
references: Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9
references: 17218844
references: Proc Natl Acad Sci U S A. 2002 May 14;99(10):6806-11
references: 12011441
references: Clin Cancer Res. 2007 Mar 15;13(6):1713-9
references: 17363524
references: N Engl J Med. 2004 Dec 9;351(24):2519-29
references: 15590954